Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, #81, Irwon-ro, Gangnam-Gu, Seoul, 06351, South Korea.
BMC Cancer. 2021 Aug 30;21(1):972. doi: 10.1186/s12885-021-08695-7.
Tumor mutation burden is an emerging biomarker for immunotherapy. Although several clinical trials for immunotherapy in lymphoma have been carried out, the mutation burden of various lymphomas is not well known yet. Thus, the objective of this study was to compare tumor mutation burden of various non-Hodgkin lymphomas using panel based massively parallel sequencing.
We conducted 405 gene panel based massively parallel sequencing of 300 non-Hodgkin lymphomas and investigate the number of SNV/Indel in each lymphoma.
The number of SNV/Indel was higher in mature B-cell lymphoma than in mature T- and NK-cell lymphoma. (P < 0.001) The number of SNV/Indel in primary mediastinal large B-cell lymphoma and primary diffuse large B-cell lymphoma of the central nervous system was the highest, which was significantly higher than that in diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS).(P = 0.030 and P = 0.008, respectively) The SNV/Indel number in EBV-positive DLBCL NOS was significantly lower than that in DLBCL NOS. (P = 0.048) Peripheral T-cell lymphoma, NOS showed no significant difference in the number of SNV/Indel from extranodal NK/T-cell lymphoma, nasal type (P = 0.942) or angioimmunoblastic T-cell lymphoma (P = 0.739). The number of SNV/Indel in anaplastic large cell lymphoma, ALK-positive was significantly lower than that in anaplastic large cell lymphoma, ALK-negative (P = 0.049). It was the lowest among all the lymphomas considered.
Various lymphomas have different mutation burdens. Thus, tumor mutation burden can be used as a promising biomarker for immunotherapy in lymphomas.
肿瘤突变负担是免疫治疗的一个新兴生物标志物。虽然已经进行了几项淋巴瘤免疫治疗的临床试验，但各种淋巴瘤的突变负担尚不清楚。因此，本研究的目的是使用基于panel 的大规模平行测序比较各种非霍奇金淋巴瘤的肿瘤突变负担。
我们对 300 例非霍奇金淋巴瘤进行了 405 个基因panel 的基于panel 的大规模平行测序，并研究了每种淋巴瘤中的 SNV/Indel 数量。
成熟 B 细胞淋巴瘤中的 SNV/Indel 数量高于成熟 T 和 NK 细胞淋巴瘤。（P<0.001）原发性纵隔大 B 细胞淋巴瘤和原发性中枢神经系统弥漫性大 B 细胞淋巴瘤的 SNV/Indel 数量最高，明显高于弥漫性大 B 细胞淋巴瘤，未另作说明（DLBCL NOS）。（P=0.030 和 P=0.008）EBV 阳性 DLBCL NOS 的 SNV/Indel 数量明显低于 DLBCL NOS。（P=0.048）外周 T 细胞淋巴瘤，NOS 与结外 NK/T 细胞淋巴瘤，鼻型（P=0.942）或血管免疫母细胞性 T 细胞淋巴瘤（P=0.739）的 SNV/Indel 数量无显著差异。ALK 阳性间变性大细胞淋巴瘤，ALK 的 SNV/Indel 数量明显低于 ALK 阴性间变性大细胞淋巴瘤（P=0.049）。它是所有考虑的淋巴瘤中最低的。
各种淋巴瘤的突变负担不同。因此，肿瘤突变负担可用作淋巴瘤免疫治疗的有前途的生物标志物。
